RESUMEN

We sought to determine whether patients requiring more aphereses to obtain adequate numbers of CD34+ cells had delayed hematopoietic recovery following autologous transplantation. We identified 496 consecutive individuals with lymphoma who underwent hematopoietic stem cell mobilization using etoposide and G-CSF and first autologous transplantation. In multivariate analysis, increased apheresis days as a continuous and as a categorical variable at ≥5/<5 days significantly predicted neutrophil recovery. Apheresis days fell just short of significance (P=0.06) as a predictor of platelet recovery in multivariate analysis. Increased apheresis days (as both continuous and categorical variables) were also predictive of treatment-related myelodysplastic syndrome/AML. Patients who underwent ≥5 days of pheresis had significantly worse survival (P=0.001) than patients with less pheresis days owing to significantly higher relapse mortality (P=0.001).

Asunto(s)

Antígenos CD34 , Eliminación de Componentes Sanguíneos , Hematopoyesis , Movilización de Célula Madre Hematopoyética , Células Madre Hematopoyéticas , Linfoma , Trasplante de Células Madre de Sangre Periférica , Recuperación de la Función , Adolescente , Adulto , Anciano , Antineoplásicos Fitogénicos/administración & dosificación , Bases de Datos Factuales , Supervivencia sin Enfermedad , Etopósido/administración & dosificación , Femenino , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Humanos , Linfoma/mortalidad , Linfoma/terapia , Masculino , Persona de Mediana Edad , Recuento de Plaquetas , Estudios Retrospectivos , Tasa de Supervivencia , Trasplante Autólogo